Discover the transformation of antibody-drug conjugates (ADCs) from experimental to essential in cancer therapy with new ...
Artificial intelligence research biotech Earendil Labs has penned an $885 million deal to use WuXi XDC’s linker-payload technology to create next-gen antibody-drug conjugates. | AI research biotech ...
Antibody-drug conjugates (ADCs) represent the most successful class of active targeting drug-delivery systems, however, despite the increasing number of FDA approvals treatment-related adverse events ...
Antibody-Drug Conjugates (ADCs) are a fast-growing modality in both cancerous and non-cancerous indications. To date 15 ADCs have been approved by the regulatory agencies as therapies for various ...
Under the agreement, WuXi XDC will grant Earendil Labs an exclusive global license to its proprietary WuXiTecan-2 ...
Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN021, an independently developed innovative dual payload bispecific antibody-drug conjugate ...
PALO ALTO, CA, UNITED STATES, August 13, 2025 / EINPresswire.com / -- Baylink Biosciences, a biotechnology company pioneering next-generation antibody-drug conjugate (ADC) technologies, today ...
Tubulis today announced the publication of preclinical proof-of-concept data for its novel Alco5 conjugation platform in Nature Communications. The paper describes the company’s novel antibody-drug ...
Antibody-drug conjugate (ADC) is a promising class of cancer treatments with accelerating U.S. Food and Drug Administration (FDA) approval and rapidly growing market size as discussed in previous ...
Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, today announced a strategic collaboration with WuXi XDC Cayman Inc. ('WuXi XDC', stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results